Medical device company Polarean Imaging plc (AIM: POLX) announced on Wednesday that it has signed a trade-in agreement with the University of Kansas Medical Center (KUMC) to replace its existing research hyperpolariser with a new clinical-grade Xenon MRI hyperpolariser system. This upgrade aims to advance KUMC's research in various therapeutic areas, including asthma, cystic fibrosis, long COVID, pulmonary hypertension, interstitial lung disease and scleroderma.
KUMC, a leading academic centre in Xenon MRI research, will receive the new FDA-approved system later this year. Polarean will collaborate with KUMC to enhance clinical imaging, NIH-funded research and pharmaceutical-sponsored trials.
Dr Peter Niedbalski, a KUMC researcher, recently secured a grant for a multi-centre study using Xenon MRI to explore structural determinants of low lung function and respiratory symptoms in young adults.
Polarean is revolutionising pulmonary medicine with its FDA-approved hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW. The company's technology provides non-invasive, radiation-free imaging to assess lung function, addressing the needs of over 500 million chronic respiratory disease patients worldwide. Founded in 2012 and operating from Durham, NC and London, Polarean focuses on developing and commercialising innovative imaging solutions.
Magellan Health launches Teen Mental Wellbeing app powered by BeMe
Azenta names new president and CEO
PHC announces launch of LiCellMo live cell metabolic analyzer targeting CGT advancements
Expanse Medical names new chief executive officer and FlowPhysix board member
ClariMed opens new Leeds, UK office
Qaelon Medical names new chief executive officer
Johnson & Johnson agrees acquisition of V-Wave
Nightingale Health gains UKCA certification and expands with new laboratory
Talphera enrols first subject in NEPHRO CRRT study
China Pharma Holdings anticipates launch of Dry Eye Disease Therapeutic Device in early 2025
SOPHiA DDM Platform achieves IVDR certification, enhancing diagnostic precision
Medtronic reports FDA approval of Simplera CGM; partners with Abbott
OncoBeta expands Rhenium-SCT (Skin Cancer Therapy) treatment services in Italy